Keros Therapeutics Inc (KROS)
Healthcare
Biotechnology
10.60 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
0.2Mrd. $
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
20Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
89.9%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
1.0
Performance
Perf. 1M
Price performance over the last month.
-4.00%
Perf. 3M
Price performance over the last 3 months.
3.00%
Perf. 6M
Price performance over the last 6 months.
-48.80%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-46.00%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-53.8%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
48.8
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
–
P/B
Price-to-book ratio: market value relative to book equity.
–
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
6.2
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
-13.0
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
–
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
-184.9%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-256.6%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-16.8%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-12.2%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
–
fortress balance sheet
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
13.11
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
3 von 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
0.00%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
0.00%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
6,774.96%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
344.71%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
-7.80%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
4
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
15
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
42
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
3 von 9
Fundamental Rating
Our own Fundamental Rating from −100 to +100 with an A+ to F grade: growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety, all percentile-ranked.
D (-34 von 100)
fortress balance sheet
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
13.11
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.14 | – | 3 | 2,027.30 | -1,513.00 | -46 | -46 |
| 2025: Q1 | 3.62 | – | 211 | 254,413.30 | 70.30 | 161 | 161 |
| 2025: Q2 | -0.76 | – | 18 | 49,002.70 | -169.00 | -30 | -30 |
| 2025: Q3 | -0.18 | – | 14 | 3,575.80 | -51.00 | 3 | 3 |
| 2025: Q4 | -0.62 | – | 0 | -87.30 | -6,093.80 | -27 | -27 |
| 2026: Q1 | -0.63 | -117.30 | 0 | -99.80 | -6,459.90 | -4 | -4 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Keros Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
| Employees | 87 |
|---|---|
| Headquarters | Lexington, MA |
| Website | kerostx.com |
| IPO Date | 8. Apr 2020 |
| Next Earnings | 5. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Jasbir S. Seehra Ph.D. | President, CEO & Director | 1956 |
| Keith C. Regnante MBA | Chief Financial Officer | 1970 |
| Esther Cho J.D. | Chief Legal Officer & Secretary | 1989 |
| Justin Frantz | Head of Investor Relations | – |
| Lorena Lerner Ph.D. | Chief Scientific Officer | 1972 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.